

Opportunity Title: FDA Studying the Critical Quality Attributes of Multispecific Antibodies/Fusion Proteins (SARITA 4400)

Opportunity Reference Code: FDA-CDER-2026-0087

Organization U.S. Food and Drug Administration (FDA)

Reference Code FDA-CDER-2026-0087

How to Apply *To submit your application, scroll to the bottom of this opportunity and click APPLY.*

A complete application consists of:

- An application
- Transcripts – [Click here for detailed information about acceptable transcripts](#)
- A current resume/CV, including academic history, employment history, relevant experiences, and publication list
- One educational or professional recommendation

All documents must be in English or include an official English translation.

If you have questions, send an email to ORISE.FDA.CDER@orau.org. Please include the reference code for this opportunity in your email.

Application Deadline 5/31/2026 3:00:00 PM Eastern Time Zone

Description ***Applications will be reviewed on a rolling-basis.**


FDA Office and Location: A research opportunity is available within the Food and Drug Administration (FDA) in The Center for Drug Evaluation and Research (CDER), located at White Oak, Maryland.

The Center for Drug Evaluation and Research (CDER) performs an essential public health task by making sure that safe and effective drugs are available to improve the health of people in the United States. As part of the U.S. Food and Drug Administration (FDA), CDER regulates over-the-counter and prescription drugs, including biological therapeutics and generic drugs. This effort covers more than just medicines.

Research Project: Under the guidance of the mentor, you will help investigate critical quality attributes of trispecific antibodies and trispecific fusion proteins. Using breast and ovarian cancer cell models, you will help develop bioassays to evaluate and improve the quality, safety, and anti-tumor activity of FDA-regulated products.

Learning Objectives: During the appointment, you will learn how to:

- Design bispecific and trispecific antibodies/fusion proteins using genetic engineering approaches while applying appropriate structural and functional considerations.
- Conduct experiments for the expression and production of bispecific and trispecific antibodies/fusion proteins.
- Perform physicochemical and biological characterization of bispecific and trispecific antibodies and fusion proteins.
- Design and develop optimized bioassays that detect signal transduction



ORISE GO

The ORISE GO mobile app helps you stay engaged, connected and informed during your ORISE experience – from application, to offer, through your appointment and even as an ORISE alum!

Visit ORISE GO 

GET IT ON
 **Google Play**

Download on the
 **App Store**

Opportunity Title: FDA Studying the Critical Quality Attributes of Multispecific Antibodies/Fusion Proteins (SARITA 4400)

Opportunity Reference Code: FDA-CDER-2026-0087

downstream of receptor binding and identify signal transduction pathways most relevant to the mechanism of action of incompletely characterized products.

- Apply acquired knowledge and skills in ongoing research projects with the Office of Pharmaceutical Quality Research's (OPQR) research and regulatory mission while advancing professional development in antibody therapeutics.

Mentor: The mentor for this opportunity is Wen Jin Wu

(wen.wu@fda.hhs.gov). If you have questions about the nature of the research, please contact the mentor.

Anticipated Appointment Start Date: April/May, 2026. Start date is flexible and will depend on a variety of factors.

Appointment Length: The appointment will initially be for one year, but may be renewed upon recommendation of FDA and is contingent on the availability of funds.

Level of Participation: The appointment is full time.

Participant Stipend: The participant will receive a monthly stipend commensurate with educational level and experience.

Citizenship Requirements: This opportunity is available to U.S. citizens, Lawful Permanent Residents (LPR), and foreign nationals. Non-U.S. citizen applicants should refer to the [Guidelines for Non-U.S. Citizens Details page](#) of the program website for information about the valid immigration statuses that are acceptable for program participation.

This program, administered by ORAU through its contract with the U.S. Department of Energy to manage the Oak Ridge Institute for Science and Education, was established through an interagency agreement between DOE and FDA. The participant will receive a monthly stipend commensurate with educational level and experience. Proof of health insurance is required for participation in this program. Participants do not become employees of FDA, DOE or the program administrator, and there are no employment-related benefits.

Completion of a successful background investigation by the Office of Personnel Management is required for an applicant to be on-boarded at FDA. OPM can complete a background investigation only for individuals, including non-US Citizens, who have resided in the US for a total of three of the past five years.

FDA Ethics Requirements

If an ORISE Fellow, to include their spouse and minor children, reports what is identified as a Significantly Regulated Organization (SRO) or prohibited investment fund financial interest in any amount, or a relationship with an SRO, except for spousal employment with an SRO, and the individual will not voluntarily divest the financial interest or terminate the

Opportunity Title: FDA Studying the Critical Quality Attributes of Multispecific Antibodies/Fusion Proteins (SARITA 4400)

Opportunity Reference Code: FDA-CDER-2026-0087

relationship, then the individual is not placed at FDA. For additional requirements, see [FDA Ethics for Nonemployee Scientists](#).

FDA requires ORISE participants to read and sign their FDA Education and Training Agreement within 30 days of his/her start date, setting forth the conditions and expectations for his/her educational appointment at the agency. This agreement covers such topics as the following:

- Non-employee nature of the ORISE appointment;
- Prohibition on ORISE Fellows performing inherently governmental functions;
- Obligation of ORISE Fellows to convey all necessary rights to the FDA regarding intellectual property conceived or first reduced to practice during their fellowship;
- The fact that research materials and laboratory notebooks are the property of the FDA;
- ORISE fellow's obligation to protect and not to further disclose or use non-public information.

Qualifications The qualified candidate should have received a doctoral or equivalent degree with an educational background in molecular and cell biology, biochemistry, biotechnology, immunology, pharmacology, toxicology. Degree must have been received within the past five years.

Point of Contact [Ashley](#).

- Eligibility**
- **Degree:** Doctoral Degree received within the last 60 month(s).
- Requirements**
- **Discipline(s):**
 - **Life Health and Medical Sciences** ([5](#) )

Affirmation I am a U.S. citizen, or I have lived in the United States for at least 36 out of the past 60 months. (36 months do not have to be consecutive.)
and
I have read the FDA Ethics Requirements.